Gewählte Publikation:
SHR
Neuro
Krebs
Kardio
Lipid
Stoffw
Microb
Mader, JK; Lilly, LC; Aberer, F; Korsatko, S; Strock, E; Mazze, RS; Damsbo, P; Pieber, TR.
A feasibility study of a 3-day basal-bolus insulin delivery device in individuals with type 2 diabetes.
Diabetes Care. 2014; 37(5):1476-1479
Doi: 10.2337/dc13-2238
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
-
Mader Julia
-
Pieber Thomas
- Co-Autor*innen der Med Uni Graz
-
Aberer Felix
-
Korsatko Stefan
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
-
This study tested the feasibility of transition from multiple daily injections (MDI) to a 3-day, basal-bolus insulin delivery device (PaQ) for type 2 diabetes (T2D).
Twenty MDI-treated individuals with T2D with HbA(1c) ≤9% (75 mmol/mol) were enrolled in a single-center, single-arm pilot study, lasting three 2-week periods: baseline (MDI), transition to PaQ, and PaQ therapy. Feasibility of use, glycemic control, safety, and patient satisfaction were assessed.
Nineteen participants transitioned to PaQ treatment and demonstrated competency in assembling, placing, and using the device. Self-monitored blood glucose and blinded continuous glucose-monitoring data showed glycemic control similar to MDI. Study participants reported high satisfaction and device acceptance.
PaQ treatment is both feasible and acceptable in individuals with T2D. Transition from MDI is easy and safe. PaQ treatment might lead to better therapy adherence and improvements in glycemic control and clinical outcomes.
- Find related publications in this database (using NLM MeSH Indexing)
-
Adult -
-
Aged -
-
Blood Glucose - analysis
-
Diabetes Mellitus, Type 2 - drug therapy
-
Drug Administration Schedule -
-
Feasibility Studies -
-
Female -
-
Humans -
-
Hypoglycemic Agents - administration & dosage
-
Insulin - administration & dosage
-
Insulin Infusion Systems -
-
Male -
-
Middle Aged -
-
Patient Satisfaction -
-
Pilot Projects -